Ordering
Available Variants10 mg
CHA.36826-10mg
Price
€89.60
Available – Dispatch in 14 days
50 mg
CHA.36826-50mg
Price
€365.60
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.36826-10mg | €89.60 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.36826-50mg | €365.60 |
≥98% (HPLC), nRTI inhibitor, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C19H30N5O10P · C4H4O4 |
|---|---|
| CAS Number | 202138-50-9 |
| Molecular Weight | 635.51 |
| UNSPSC Code | 12352200 |
| PubChem Substance ID | 329826069 |
| NACRES | NA.77 |
| MDL number | MFCD08141829 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS08
GHS07
  GHS08,GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H319,H373,H412 |
| pcodes | P260 - P264 - P273 - P280 - P305 + P351 + P338 - P314 |
| Hazard Classifications | Aquatic Chronic 3 - Eye Irrit. 2 - STOT RE 2 |
| target_organs | Bone,Kidney |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Tenofovir disoproxil fumarate, with a chemical abstracts service number of 202138-50-9, is a pharmaceutical compound utilized in the treatment and prevention of HIV/AIDS and hepatitis B. As a nucleotide reverse transcriptase inhibitor, it functions by inhibiting the replication of viral DNA, thereby reducing the viral load in infected individuals. The disoproxil fumarate salt form of tenofovir enhances its oral bioavailability, allowing for effective administration via oral routes. Tenofovir disoproxil fumarate is commonly prescribed in combination with other antiretroviral agents to achieve optimal therapeutic outcomes. Its efficacy and safety profile have been extensively evaluated in clinical trials, demonstrating its value as a key component in the management of HIV and hepatitis B infections. The compounds pharmacokinetic properties and resistance profile are also well-characterized, supporting its widespread use in clinical practice.
